Drug-drug interaction study of S-217622
Phase 1
- Conditions
- COVID-19
- Registration Number
- JPRN-jRCT2031210595
- Lead Sponsor
- agata Tsutae
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Japanese healthy adult male and female participants
Exclusion Criteria
History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Digoxin, Rosuvastatin, Metformin: Cmax, Tmax, AUC0-last, AUC0-inf, t1/2,z, lamdaz, MRT, CL/F, Vz/F<br>S-217622: Cmax, Tmax, AUC0-96<br>Adverse events, physical examination, laboratory tests, vital signs, 12-lead ECG
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie S-217622's drug-drug interactions in JPRN-jRCT2031210595?
How does S-217622 compare to remdesivir in preclinical SARS-CoV-2 viral load reduction models?
Which biomarkers correlate with S-217622 efficacy in COVID-19 pathogenesis pathways?
What adverse event profiles are observed with S-217622 in phase I trials for viral infections?
Are there synergistic combinations of S-217622 with protease inhibitors in SARS-CoV-2 treatment?